Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00040521 | Study Evaluating rhIL-11 in Active Crohn's Disease | PHASE2 | COMPLETED | - | — | — | Apr 1, 2002 | Oct 1, 2003 | Feb 8, 2013 | 2 | United States |
| Name | Type | Description |
|---|---|---|
| Recombinant Human Interleukin-11 (rhIL-11) | DRUG | - |
Inclusion Criteria: * Documented, signed and dated informed consent to participate in this trial prior to any study related procedures being performed. * Men and women age 16 years and over. * Diagnosis of Crohn's disease for at least 6 months that has been appropriately documented and confirmed by...